Mirum Pharmaceuticals Q3 EPS $(0.57) Beats $(0.65) Estimate, Sales $47.73M Beat $37.12M Estimate
Portfolio Pulse from mahesh@benzinga.com
Mirum Pharmaceuticals reported Q3 earnings per share of $(0.57), beating the analyst consensus estimate of $(0.65) by 12.31%. This is a 44.12% increase over losses from the same period last year. The company also reported quarterly sales of $47.73 million, beating the analyst consensus estimate of $37.12 million by 28.57%. This is a 154.13% increase over sales from the same period last year.
November 02, 2023 | 8:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals reported better than expected Q3 earnings and sales, which could positively impact the stock price.
Mirum Pharmaceuticals reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100